This is a safety, tolerability and pharmacokinetics study of AGN-190168 in subjects with acne vulgaris.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Enrollment
78
AGN-190168 Formulation 1 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
AGN-190168 Formulation 2 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
Tazarotene gel 0.1% applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
Unnamed facility
College Station, Texas, United States
Maximum Plasma Level (Cmax) of AGN-190168
Time frame: Day 29
Maximum Plasma Level (Cmax) of AGN-190168 Metabolite
Time frame: Day 29
Local Dermal Tolerability as Assessed by the Subject Using a 4-Point Scale
Time frame: Day 29
Local Dermal Tolerability as Assessed by the Investigator Using a 4-Point Scale
Time frame: Day 29
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Tazarotene cream 0.1% cream applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.